Thousand Oaks-based Amgen won approval from the U.S. Food and Drug Administration on May 17 for its new monthly migraine treatment Aimovig. “Migraine is a serious neurological disease that has dramatic effects on patients’ lives,” Sean Harper, executive vice president of research and development, said in a news release. “Migraine patients experience excruciating headache pain,…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
